Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.00126 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Georg Pfeiler und 51 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Neutropenia. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
PURPOSE BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Vienna, Austria.
- Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
- Dana-Farber/Partners Cancer Care, Boston, MA.
- Breast Health Center, St Francis Hospital, Vienna, Austria.
- Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
- Winship Cancer Institute, Emory University, Atlanta, GA.
ORCID-Profile: Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Miguel Martin, Nicholas Zdenkowski, Sibylle Loibl, Marija Balic, Haeseong Park, Claudine Isaacs, Justin M Balko, Judith Bliss, Harold Burstein, Fatima Cardoso, Theodoros Foukakis, Karen A Gelmon, Matthew Goetz, Tufia C Haddad, Hiroji Iwata, Jacek Jassem, Soo-Chin Lee, Eleftherios P Mamounas, Kathy D Miller, Elisabetta Munzone, Einav Nili Gal-Yam, Lois Shepherd, Christian Singer, Christoph Thomssen, Ling-Ming Tseng, Pinuccia Valagussa, Eric P Winer, Antonio C Wolff, Gabriele Zoppoli, Celine Schurmans, Xin Huang, Eric Gauthier, Christian Fesl, Amylou C Dueck, Angela DeMichele, Michael Gnant
Förderung
- Cancer Research UK
Zitieren
APA
Pfeiler, G., Hlauschek, D., Mayer, E. L., Deutschmann, C., Kacerovsky-Strobl, S., Martin, M., Meisel, J. L., Zdenkowski, N., Loibl, S., Balic, M., Park, H., Prat, A., Isaacs, C., Bajetta, E., Balko, J. M., Bellet-Ezquerra, M., Bliss, J., Burstein, H., Cardoso, F., …, & PALLAS Groups and Investigators (2023). Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00126
Vancouver
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00126
BibTeX
@article{Pfeiler2023,
author = {Pfeiler, Georg and Hlauschek, Dominik and Mayer, Erica L and Deutschmann, Christine and Kacerovsky-Strobl, Stephanie and Martin, Miguel and Meisel, Jane Lowe and Zdenkowski, Nicholas and Loibl, Sibylle and Balic, Marija and Park, Haeseong and Prat, Aleix and Isaacs, Claudine and Bajetta, Emilio and Balko, Justin M and Bellet-Ezquerra, Merixtell and Bliss, Judith and Burstein, Harold and Cardoso, Fatima and Fohler, Hannes and Foukakis, Theodoros and Gelmon, Karen A and Goetz, Matthew and Haddad, Tufia C and Iwata, Hiroji and Jassem, Jacek and Lee, Soo-Chin and Linderholm, Barbro and Los, Maartje and Mamounas, Eleftherios P and Miller, Kathy D and Morris, Patrick G and Munzone, Elisabetta and Gal-Yam, Einav Nili and Ring, Alistair and Shepherd, Lois and Singer, Christian and Thomssen, Christoph and Tseng, Ling-Ming and Valagussa, Pinuccia and Winer, Eric P and Wolff, Antonio C and Zoppoli, Gabriele and Machacek-Link, Jana and Schurmans, Celine and Huang, Xin and Gauthier, Eric and Fesl, Christian and Dueck, Amylou C and DeMichele, Angela and Gnant, Michael and PALLAS Groups and Investigators, PALLAS Groups and Investigators},
title = {Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.00126}
}
EUVIMED